Literature DB >> 15166463

Standards for the assay of Creutzfeldt-Jakob disease specimens.

P Minor1, J Newham2, N Jones1, C Bergeron3, L Gregori4, D Asher5, F van Engelenburg6, T Stroebel7, M Vey8, G Barnard9, M Head10.   

Abstract

Assays for the agent of Creutzfeldt-Jakob disease (CJD) include measurement of infectivity in different animal systems, such as wild-type or transgenic mice, and detection of PrP(Sc) by different methods and formats. The various assays could be best calibrated against each other by use of uniform readily available materials, and samples of four human brains, two from sporadic CJD patients, one from a variant CJD patient and one from a non-CJD patient, have been prepared as 10% homogenates dispensed in 2000 vials each for this purpose. Results of in vitro methods, particularly immunoblot assays, were compared in the first collaborative study described here. While dilution end-points varied, the minimum detectable volume was surprisingly uniform for most assays and differences in technical procedure, other than the sample volume tested, had no detectable systematic effect. The two specimens from sporadic CJD cases contained both type 1 and type 2 prion proteins in approximately equal proportions. The materials have been given the status of reference reagents by the World Health Organization and are available for further study and assessment of other in vitro or in vivo assay procedures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166463     DOI: 10.1099/vir.0.79959-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Rapid Testing for Creutzfeldt-Jakob Disease in Donors of Cornea.

Authors:  Luisa Gregori; Arthur R Serer; Kristy L McDowell; Juraj Cervenak; David M Asher
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Diagnosis of human prion disease.

Authors:  Jiri G Safar; Michael D Geschwind; Camille Deering; Svetlana Didorenko; Mamta Sattavat; Henry Sanchez; Ana Serban; Martin Vey; Henry Baron; Kurt Giles; Bruce L Miller; Stephen J Dearmond; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-01       Impact factor: 11.205

3.  The octarepeat region of the prion protein is conformationally altered in PrP(Sc).

Authors:  Alice Y Yam; Carol Man Gao; Xuemei Wang; Ping Wu; David Peretz
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

4.  Characterization of prion protein (PrP)-derived peptides that discriminate full-length PrPSc from PrPC.

Authors:  Anthony L Lau; Alice Y Yam; Melissa M D Michelitsch; Xuemei Wang; Carol Gao; Robert J Goodson; Robert Shimizu; Gulliver Timoteo; John Hall; Angelica Medina-Selby; Doris Coit; Colin McCoin; Bruce Phelps; Ping Wu; Celine Hu; David Chien; David Peretz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-29       Impact factor: 11.205

5.  Direct detection of disease associated prions in brain and lymphoid tissue using antibodies recognizing the extreme N terminus of PrPC.

Authors:  Geoff Barnard; Lee Hopkins; Sowmiya Moorthie; David Seilly; Paul Tonks; Reza Dabaghian; Jonathan Clewley; John Coward; Ian McConnell
Journal:  Prion       Date:  2007-04-15       Impact factor: 3.931

6.  Detection of type 1 prion protein in variant Creutzfeldt-Jakob disease.

Authors:  Helen M Yull; Diane L Ritchie; Jan P M Langeveld; Fred G van Zijderveld; Moira E Bruce; James W Ironside; Mark W Head
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  Prion potentiation after life-long dormancy in mice devoid of PrP.

Authors:  Davy Martin; Fabienne Reine; Laetitia Herzog; Angélique Igel-Egalon; Naima Aron; Christel Michel; Mohammed Moudjou; Guillaume Fichet; Isabelle Quadrio; Armand Perret-Liaudet; Olivier Andréoletti; Human Rezaei; Vincent Béringue
Journal:  Brain Commun       Date:  2021-04-28

8.  Protease-resistant prion protein in lymphoreticular tumors of variant Creutzfeldt-Jakob disease mice.

Authors:  Larisa Cervenakova; Oksana Yakovleva; Carroll McKenzie
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

9.  Human tonsil-derived follicular dendritic-like cells are refractory to human prion infection in vitro and traffic disease-associated prion protein to lysosomes.

Authors:  Zuzana Krejciova; Paul De Sousa; Jean Manson; James W Ironside; Mark W Head
Journal:  Am J Pathol       Date:  2013-11-01       Impact factor: 4.307

Review 10.  A closer look at prion strains: characterization and important implications.

Authors:  Laura Solforosi; Michela Milani; Nicasio Mancini; Massimo Clementi; Roberto Burioni
Journal:  Prion       Date:  2013-01-28       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.